A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma (PHILEMON)

Lund University Hospital

Status and phase

Completed

Phase 2

Conditions

Relapsed/Refractory Mantle Cell Lymphoma

Treatments

Drug: Rituximab

Drug: Lenalidomide

Drug: Ibrutinib

Study type

Interventional

Funder types

Other

NETWORK

Industry

Identifiers

NCT02460276

NLG-MCL6

Details and patient eligibility

About

In this trial, patients with mantle cell lymphoma will be included, treatment with lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12 cycles, cycle length 28 days. Patients with complete remission, partial response or stable disease will enter a maintenance phase with treatment with ibrutinib and rituximab until progression of disease.

The primary objective is to evaluate overall response rate, based on PET and CT.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age over 18 years
Histologically confirmed (according to the WHO 2008, and upcoming 2015 classification) mantle cell lymphoma stage II-IV
Received at least 1 prior rituximab-containing chemotherapy regimen
Documented relapse or disease progression following the last anti-mantle cell lymphoma treatment
At least 1 measurable site of disease (over 1.5 cm long axis)
WHO performance status 0-3
Written informed concent
Female subjects of childbearing potential must:
1. Understand that the study medication is expected to have a teratogenic effect
2. Agree to use, and be able to comply with, highly effective contraception without interruption, 4 weeks Before start study drug, throughout study drug therapy (including dose interruptions) and for 12 months after the end of study drug therapy, even if she has amenorrhoea
3. Women of childbearing potential must have a negative serum (beta-human ionic gonadotropin or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study
Male subjects must:
1. Agree to use condoms throughout study drug therapy, during any dose interruption and for 3 months after cessation of study therapy if their partner is of childbearing potential and has no contraception
2. Agree not to donate semen during study drug therapy and for 3 months after end of study drug therapy
All subjects must agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy
All subjects must agree not to share study medication with another person and to return all unused study drug to the investigator
Absolute neutrophil Count (ANC) ≥ 1000/mm3
Platelets ≥ 100,000/mm3 or ≥50,000/mm3 if bone marrow involvement independent of transfusion support in either situation
Alanine aminotransferase (ALT) and aspartate aminotransferase ≤ 3 x upper limit of normal (ULN).
Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockcroft-Gault) ≥ 40 mL/min/1.73 m2
Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study

Exclusion criteria

Chemotherapy or radiotherapy within 3 weeks, therapeutic antibodies within 4 weeks, radioimmunotherapy within 10 weeks, or major surgery within 4 weeks of inclusion
Known central nervous system lymphoma
Other active malignancy
Psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study
Requirement of corticosteroid therapy at a dose > 10 mg prednisolone/day
Major surgery within 4 weeks of inclusion
History of stroke or intracranial hemorrhage within 6 months prior to inclusion
Requirement of anticoagulation treatment with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon)
Requirement of treatment with strong or moderate CYP3A inhibitors
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Vaccination with live, attenuated vaccines within 4 weeks of inclusion
Known history of human immunodeficiency virus (HIV) or Active hepatitis C Virus or Active Hepatitis B Virus infection or any uncontrolled Active systemic infection requiring intravenous antibiotics
Any Life-threatening illness, Medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules or lenalidomide tablets, or put the study outcomes at undue risk
Known hypersensitivity or allergy to rituximab, lenalidomide or ibrutinib